Liquid Biopsy Markets: Global Analysis and Opportunity Evaluation 2016 - 2020

 
$5,704.80/ £4,754.00 
.  
     
Customer Support
+44 (0)1487 843 722


 
Untitled Document

This market report gives a comprehensive and easy-to-review analysis of the liquid biopsy market 2016 – 2020. It provides key market data and identifies new and emerging opportunities relating to circulating tumour cells (CTCs) and circulating cell-free DNA and RNA (cfDNA and cfRNA). The analysis is based on primary data disclosed by experienced end-users’ in the clinical, diagnostics and research fields on their current liquid biopsy practices and their plans over the next three. Its findings provide a wealth of market information on the liquid biopsy market and enables suppliers to reduce costs, identify new markets and compete more effectively in the global marketplace.

Circulating Tumour Cells (CTCs)
 
Current and 3-year CTC activity disclosures provided by 482 scientists and clinicians
Growth in CTC tests and estimated growth over the next 3 years (±% change)
End-users' estimates of the costs per patient, for CTC tests
CTC detection/enrichment platforms used currently and in 3 years (±% change)
Company CTC platforms used currently and over the next 3 years (±% change)
CTC parameters or measurements now and in 3 years (±% change)
Non-Molecular techniques used with CTCs, currently and in 3 years (±% change)
Molecular techniques used with CTCs, now and in 3 years (±% change)
Suppliers of molecular techniques currently and anticipated in 3 years (±% change)
Markers used to enrich or characterise CTCs now and in 3 years (±% change)
CTC subpopulation studies currently and anticipated in 3 years (±% change)
Molecular forms studied currently and anticipated in 3 years (±% change)
Molecular biomarkers studied currently and anticipated in 3 years (±% change)
Sample types studied currently for the purpose of CTC studies
End-users' disclosures on the clinical utilities of CTCs in diagnostics
Cancer types studied relating to the study of CTCs
Purpose of studies relating to CTCs
Limitations of current studies of CTCs
Fields or sectors
Global regions, countries and organisation types
The study or investigation of CTCs in drug R&D
The study or investigation of CTC in drug R&D by R&D development phase
The use of CTCs as companion diagnostics now and in 3 years (±% change)
   
Free Circulating Nucleic Acids (CNAs)
 
Growth in cfDNA and cfRNA tests and over the next 3 years (±% change)
Cost estimates per sample, by scientists and clinicians, for patient CNA tests
Molecular techniques used with cfDNA and cfRNA, now and in 3 years (±% change)
Suppliers of molecular techniques currently and anticipated in 3 years (±% change)
Suppliers of kits for the enrichment or isolation of cfDNA and cfRNA
Molecular forms studied currently and anticipated in 3 years (±% change)
Biomarkers studied currently and anticipated in 3 years (±% change)
Sample types studied for cfDNA and cfRNA now and in 3 years (±% change)
Clinical utilities of cfDNA and cfRNA in diagnostics now and in 3 years (±% change)
Disease types studied relating to the study of cfDNA and cfRNA
Cancer types studied relating to the study of cfDNA and cfRNA
Purpose of studies relating to cfDNA and cfRNA
Limitations of current studies of cfDNA and cfRNA
Fields or sectors
Global regions, countries and organisation types
End-users' cfDNA and cfRNA studies in drug R&D now and 3 years (±% change)
End-users' cfDNA and cfRNA studies in drug R&D by R&D development phase
The study of cfDNA/cfRNA for companion diagnostics now and in 3 years (±% change)
   
Exosomes
 
The study of exosomes by end-users now and 3 years (±% change)
Disease areas relating to the study of exosomes
Preferred kits and suppliers for the isolation of exosomes


This Report


Recent years have seen the rapid development of minimally invasive diagnostic techniques in the cancer field, notably relating to so-called 'liquid biopsies'. These developments have included the study and characterisation of circulating tumour cells and (CTCs) and circulating cell-free nucleic acids (cfDNA and cfRNA). Today, around 50 companies offer techniques that image, enrich, isolate or characterise CTCs and more advanced methods are also being used to isolate and characterise cfDNA and cfRNA. Advances are also being seen in the study of CTC sub-populations, time-dependent changes and the markers used to isolate or enrich them and new methods are increasingly being applied to cfDNA and cfRNA. Both of these strategies are seeing rapid development, as researchers and developers seek to translate these methodologies and the findings they are providing, into diagnostic tests that impact on clinical care or which drive new discovery.

Nevertheless, despite the excitement these developments are creating, important and fundamental questions remain unanswered. Laboratory Markets Ltd has carried out two comprehensive studies of diagnostic developments relating to CTCs, cell-free nucleic acids (cfDNA and cfRNA) and exosomes. These were carried out to help address these questions and to assist diagnostic companies to identify and support evolving diagnostic needs in these growing fields.

This report presents the findings of a new 'liquid biopsy' market study on CTCs, circulating cell-free nucleic acids and exosomes, completed in December 2015. These findings are analysed alongside results of a study of these markets, completed eighteen months earlier. Findings from these two studies, which present the disclosures of experienced researchers and clinicians in these fields, allowed an in-depth analysis of new developments and trends being seen in these growing diagnostic market areas.

The current studies profiled 482 experienced clinicians and research scientists, and covered CTC and cfDNA and cfRNA current practices, developments, trends and three-year plans, as well as growth, shrinkage and opportunities across key areas of these diagnostic markets. Its findings provide diagnostic companies with market information on the current and evolving use or CTCs and cfDNA and cfRNA, as well as exosomes, and the techniques that are driving these developments.

Our specialised market studies are designed to assist diagnostic companies and developers to profile current and evolving market opportunities. All of our studies are carried out through specialist groups of experienced researchers and clinicians, and therefore findings are based on 'real world' market data. By providing new insights and a better understanding of end-user practices, needs and future plans, our studies help companies identify qualified leads, to sell into these markets and also support innovation and strategic planning.

Companies mentioned

More than 120 companies are mentioned in this report, namely A&A Biotechnology, AB ANALITICA, Abbott, Abcam, ABI, Abnova, ABSciex, AccuGenomics, Aczon, Adnagen, Advanced Cell Diagnostics, AdvanDx, Affymetrix, Agendia, Agilent, ALS Jena, AMNIS, Amoy Diagnostics, Angle Technology, Applied Biosystems, Argene Inc (Biomerieux), Arrayit, Asuragen, Axis Shield, Axygen Products, Bayer, BD, Beckman Coulter, Becton Dickinson, Biocept, BioGenex, BioLegend, Bioline, Biometra, Bioneer, Bio-Rad, Biovendor, Bioview, Cancer Genetics, Canopus, Caris Life Sciences, Cell Search, Cell Signaling Technology, Chemicon, Clarient, Compucyte, Cynvenio, Cytocell, Dako (Agilent), Dianova, Dynam, eBiosciences, Empire Genomics, Enzo Life Sciences, Epic Sciences, Eppendorf, Eurofins, Eurogentec, Euroimmun, Falcon Genomics, Fermantas, Filtini, Fluidigm, Fluxion, Foundation Medicine, GE Healthcare, Genetix, GenMark Diagnostics, Greiner Bio-One, IDEXX, IDT, IDVET, Ikonisys, Illumina, Interpath, Invitrogen, Invitrogen (Life Technologies), Ipsogen (Qiagen), Janssen-Veridex, Leika, Life Technologies, Luminex, Merck, MetaCell, Millipore, Miltenyi Biotech, Molecular Devices, MolecularMD, MP-Biomedicals, Myriad Genetics, Nanostring, New England Biolabs, Olink, Ortho, Oxoid, Pathology, Peqlab, Perkin Elmer, Peviva, Promega, Qiagen, R&D, Rarecells, Roche, Roche Diagnostics, Santacruz, ScreenCell, Shimadzu, Siemens, Sigma Aldrich, Silicon Systems, Stemcell Tech, StemCell Technologies, Sysmex, Takara, ThermoFisher, TiBMolBiol, Ventana (Roche), Viatar CTC Solutions, Vitatek, VWR, Zeiss and Zymo Research.

Circulating Tumour Cells

1. Growth: Based on recent trends in the number of CTC tests (i.e. number of assays) carried out in their laboratory:

Study Dec 2015: Participants estimates of by how much (% increase or % decrease) their  laboratory's work with CTCs has changed (or not) over the last three years. Also, based on current trends in the number of CTC tests (i.e. number of assays) carried out in your laboratory, participants estimates by how much (% increase or % decrease) they anticipate their CTC activities will change (or not) over the next three years.

Study1 2014: Participants estimates of by how much (% increase or % decrease) their  laboratory's work with CTCs has changed (or not) over the last three years. Also, based on current trends in the number of CTC tests (i.e. number of assays) carried out in your laboratory, participants estimates by how much (% increase or % decrease) they anticipate their CTC activities will change (or not) over the next three years.

2. CTC Test Costs

Study Dec 2015: End-users' estimates of current per-patient test costs for CTCs.

Study1 2014: End-users' estimates of current per-patient test costs for CTCs.

3. CTC Detection & Enrichment: The main CTC enrichment, isolation or detection methods (and the associated suppliers) they use in their current activities and, based on current trends or developments in their work, the main CTC enrichment, isolation or detection methods they anticipate using in their work in three years from now. The methods and suppliers considered were:

Study Dec 2015: Abnova CytoQuest™, ADNAGEN: Immunomagnetic (Adnatest®), Advanced Cell Diagnostics: CTCscope™, Affymetrix: ViewRNA CTC Kit, ALS Jena: AVISO CellCelector, AMNIS: Flow Cytometry (ImageStreamX, APOCELL: Dielectrophoretic fractionation (ApoStream®), AVIVA BIOSCIENCES: RBC/WBC depletion (Enrichment Kit), Beckman Coulter (MoFlo Astrios EQ Series), BIOCEP: Immunomagnetic (CEPir), BIOCEPT (OncoCEE-BR™), BIOFLUIDICA: Microfluidic capture bed, BIOVIEW: Scanning FISH probes (T-FISH), CANOPUS BIOSCIENCE: By visoelectric properties (CTC Platform), CELL RAFFIX: CellSelect, CELULA: Cell sorter (Mvs360), CLEARBRIDGE: Microfluidic trapping (ClearCell®), COMPUCYTE CORPORATION: Fluorescence microscopy (Maintrac®), CREATV MICROTECH: Microfilters (CellSieve™), CYNVENIO BIOSYSTEMS: Immunomagnetic (CT-QUANT), Cytomag: Rare Cells Systems™, CYTOTRACK: Detection without enrichment (CytoTrack CT4), DENOVO SCIENCES: Microfluidic, DMB Diagnostics: Maintrac®, DYNAL/THERMOFISHER: Magnetic beads (Epithelial Enrich™), EPIC SCIENCES: Caputure and imaging (Aqua™ glass slide), FACS (Any Supplier), FILTINI: Microfilter technology, FLUIDIGM: Single-cell Genomics (BioMark™), FLUXION BIOSYSTEMS: Microfluidic technology (IsoFlux), GE HEALTHCARE: Cell Density-Based (Ficoll), GENETIX ARIOL/MOLECULAR DEVICES: Automated cell imaging, GREINER BIO-ONE: Cell Gradient (OncoQuick®), IKONISYS: Imaging (Ikoniscope(TM) System), IV DIAGNOSTICS: IVDxTx platform real-time monitoring, JANSSEN (VERIDEX): Immunomagnetic (CELLSEARCH® CTC Test), Janssen- CTC-iChip, Massachusetts Gen Center: CTC-iCHIP, MetaCell: MetaCell® Tube – Based Test, METHODIST HOSPITAL RESEARCH: Aptamers and flurorescence, MILTENYI BIOTECH: Magnetic beads (MACS® Technology), ONCOLYS: Telomerase-positive cells (TelomeScan®), Own (in-house) device(s), Parsortix (Angle Technology), RARECELLS: Size-based (ISET®), RARECYTE: Immunomagnetic (AccuCyte™), SCREENCELL: Size-based (ScreenCell®), SILICON BIOSYSTEMS: Image-based (DEPArray™), SRI Biosciences’ FASTcell system., Stemcell Tech: Lymphoprep/RosetteSep™, SYNERGX CORPORATION: Polymer-Antibody (PACS™), SYSMEX: Fluorescence emission (TelomeScan®), Thermo Fisher/Cynvenio Immunomagnetic (CT-QUANT), UNIVERSITY, MONTPELLIER: Proteins from cancer cells (Epispot), Viatar CTC Solutions: ViatarTM Molecular Diagnostics System, VIATOR LAB: Photoacoustic Detection, VITATEX: Cell Adhesion matrix Technology (CAM), Vortex Biosciences: CTC Isolation Platform and others.

Study1 2014: ADNAGEN: Immunomagnetic  (Adnatest®), ADVANCED CELL DIAGNOSTICS: Detection (RNAscope®, AMNIS: Flow Cytometry (ImageStreamX, APOCELL: Dielectrophoretic fractionation (ApoStream®), AVIVA BIOSCIENCES: RBC/WBC depletion (Enrichment Kit), BIOCEP: Immunomagnetic (CEP), BIOCEPT LABORATORIES: Immunocytochemical (OncoCEE-BR™), BIOFLUIDICA: Microfluidic capture bed, BIOVIEW: Scanning FISH probes (T-FISH), CANOPUS BIOSCIENCE: By viscoelastic properties (CTC Platform), CELL TRAFFIX: Capture and imaging, CELULA: Cell sorter (Mvs360), CLEARBRIDGE: Microfluidic trapping (ClearCell®), CREATV MICROTECH: Microfilters (CellSieve™), CYNVENIO BIOSYSTEMS: Immunomagnetic (CT-QUANT), CYTOTRACK: Detection without enrichment (CytoTrack CT4), DENOVO SCIENCES: Microfluidic, DYNAL: Magnetic beads (Epithelial Enrich™), EPIC SCIENCES: Caputure and imaging (Aqua™ glass slide), FILTINI: Microfilter technology, FLUIDIGM: Single-cell Genomics (BioMark™), FLUXION BIOSYSTEMS: Microfluidic technology (IsoFlux), GE HEALTHCARE: Cell Density-Based (Ficoll), GENETIX ARIOL/MOLECULAR DEVICES: Automated cell imaging, GREINER BIO-ONE: Cell Gradient (OncoQuick®), IKONISYS: Imaging (Ikoniscope™ System), IV DIAGNOSTICS: Real-time monitoring, JANSSEN (VERIDEX): Immunomagnetic (CELLSEARCH® CTC Test), COMPUCYTE CORPORATION: Fluorescence microscopy (Maintrac®), MILTENYI BIOTECH: Magnetic beads (MACS® Technology), METHODIST HOSPITAL RESEARCH: Aptamers and flurorescence (ODOSA), ONCOLYS: Telomerase-positive cells (TelomeScan®), ANGLE TECHNOLOGY: Filter (Parsortix), RARECELLS: Size-based (ISET®), RARECYTE: Immunomagnetic (AccuCyte™), SCREENCELL: Size-based (ScreenCell®), SILICON BIOSYSTEMS: Image-based (DEPArray™), SRI INTERNATIONAL: Array scanning (FAST), STEMCELL TECHNOLOGIES: Immunodensity (RosetteSep™), SYNERGX CORPORATION: Polymer-Antibody (PACS™), SYSMEX: Fluorescence emission (TelomeScan®), UNIVERSITY, MONTPELLIER: Proteins from cancer cells (Epispot), VIATOR LAB: Photoacoustic Detection, VITATEX: Cell Adhesion matrix Technology (CAM) and any others.

4. Non-Molecular Techniques: The main non-molecular characterisation techniques that participants currently use in their CTC studies and, based on current trends or developments in their work, the main non-molecular characterisation techniques that participants anticipate using in their CTC studies in three year from now. The techniques considered included:

Study Dec 2015: Antibody tests, Bioluminescence, Cell arrays, Chemiluminescence, Chromatography, Densitometry, Electrophoresis, Enzyme assays, Filtration, Flow cytometry, Imaging, Immunoassay, Immunocytochemical, Mass Spectrometry, Microarrays, Microscopy, Radioimmunoassay, Ultrasonography, Western Blot and any others.

Study1 2014: Antibody tests, Bioluminescence, Chemiluminescence, Chromatography, Electrophoresis, Enzyme assays, Flow cytometry, Imaging, Immunoassay, Immunocytochemical, Mass Spectrometry, Microarrays, Microscopy, Radioimmunoassay, Cell arrays, Ultrasonography, Western Blot and any others.

5. Suppliers of Non-Molecular Techniques:  Participants current suppliers (of systems, kits, reagents) of their non-molecular methods used in their CTC investigations and, based on current trends or developments in their work, who they anticipate will be your main suppliers of your non-molecular methods (e.g. Systems, kits, reagents) relating to your CFTC investigation in three years from now (the 2014 study only).

6. Molecular Techniques: The main molecular characterisation techniques that participants currently use, in your CTC studies and, based on current trends and developments in their work, the main molecular characterisation techniques that they anticipate using in their CTC studies in three year from now. The techniques considered were:

Study Dec 2015: Allele-specific PCR, Arbitrarily Primed PCR (AP-PCR), Assembly PCR (Polymerase Cycling Assembly, PCA), Asymmetric PCR (A PCR), bDNA assays, Bead-Emulsion Amplification PCR (BEA), Cancer BioChip System, Classical qualitative PCR, Colony PCR, Comet assay, Conventional qualitative PCR, Cycling Probe Technology, Cytogenetic banding, Degenerate Oligonucleotide PCR (DOP-PCR), Denaturing Gradient Gel Electrophoresis (DGGE), Digital PCR (dPCR), DNA biosensors, DNA cloning, General Hybridization, General Primers PCR, Genome Expression Profiling System (GeXP), Helicase-Dependent Amplification, High resolution melting (HRM), Hot start PCR, Hybrid Capture Assay, Hyper-PCR, Immunocapture PCR, In Situ Hybridization (e.g. FISH), In-Silico PCR, Intersequence-specific PCR (ISSR), Inverse PCR, Isothermal PCR, Karyotyping (chromosomes), Ligase Chain Reaction, Ligation-Mediated PCR, Liquid Hybridization, LNA PCR, Long PCR, Loop-mediated isothermal amplification (LAMP), Methylation-Specific PCR (MSP), Microarrays, Microsphere-Based Array, Miniprimer PCR, Multilocus Sequence Typing (MLST), Multiple Loci VNTR Analysis (MLVA), Multiplex Ligation-Dependent Probe Amplification (MLPA), Multiplex PCR, Multiplex Real-Time PCR, Multiplex Taqman, Multiplexed Microsphere-Based Array, Nested PCR, Next-Generation Sequencing (NGS), Northern Blot, Nucleic Acid Sequence-Based Amplification (NASBA), Other, Overlap-Extension PCR ( Splicing by overlap extension, SOE), PAN-AC (Single Reaction Real Time PCR), Panbacterial PCR, PCR array, PCR Denaturing Gradient Gel Electrophoresis (PCR DGGE), PCR Restriction Fragment Length Polymorphism (PCR-RFLP), Phylogenetic Community Analysis, Pulsed Field Gel Glectrophoresis (PFGE), Random Amplified Polymorphic DNA (RAPD), Rapid Amplification of cDNA ENDS PCR (RACE PCR), Rapid test, Real Time/Quantitative PCR (qPCR), Restriction Fragment Length Polymorphism (RFLP), Reverse Transcription PCR (RT-PCR), RNA-seq  (Whole Transcriptome), Sanger sequencing, Single molecule PCR, Single nucleotide repeat (SNR), Single Specific Primer-Polymerase Chain Reaction (SSP-PCR), Single tube Nested-PCR, Solid Phase PCR, Southern Blot, Stem loop RT PCR, Stepdown PCR, Strand Displacement Amplification, TaqMan Real Time PCR, Techniques not requiring amplification, Temporal Temperature Gradient Gel Electrophoresis (PCR-TTGE), Thermal Asymmetric Interlaced PCR (TAIL-PCR), Touchdown PCR, Transcription-Mediated Amplification (TMA), Type-Specific PCR, Universal Fast Walking, Whole genome amplification, Other and Other (please specify).

Study 1 2014: Allele-specific PCR, Arbitrarily Primed PCR (AP-PCR), Assembly PCR (Polymerase Cycling Assembly, PCA), Asymmetric PCR (A PCR), Bead-Emulsion Amplification PCR (BEA), Classical qualitative PCR, Colony PCR, Degenerate Oligonucleotide PCR (DOP-PCR), Digital PCR (dPCR), DNA cloning, Hot start PCR, Immunocapture PCR, In Situ Hybridization (e.g. FISH), In-Silico PCR, Inverse PCR, Isothermal PCR, Ligation-Mediated PCR, Long PCR, Methylation-Specific PCR (MSP), Microarrays, Miniprimer PCR, Multiplex Ligation-Dependent Probe Amplification (MLPA), Multiplex PCR, Multiplex Real-Time PCR, Multiplex Taqman, Nested PCR, Next-Generation Sequencing, Northern Blot, PAN-AC (Single Reaction Real Time PCR), PCR array, PCR Denaturing Gradient Gel Electrophoresis (PCR DGGE), PCR Restriction Fragment Length Polymorphism (PCR-RFLP), Real time PCR (qPCR), Random Amplified Polymorphic DNA (RAPD), Rapid Amplification of cDNA ENDS PCR (RACE PCR), Reverse Transcription PCR (RT-PCR), Sequencing (Sanger), Single molecule PCR, Single Specific Primer-Polymerase Chain Reaction (SSP-PCR), Solid Phase PCR, Southern Blot, Stem loop RT PCR, Taqman, Temporal Temperature Gradient Gel Electrophoresis (PCR-TTGE), Touchdown PCR, Transcription-Mediated Amplification (TMA) and other techniques.

7. Molecular Suppliers:  The main current suppliers (molecular systems, kits, reagents of molecular methods (e.g. Systems, kits, reagents), relating to participant's CTC investigations and, based on current trends or developments in their work, the main suppliers of molecular methods (e.g. Systems, kits, reagents) that participants anticipate purchasing from in three years from now. The organisations considered were

Study Dec 2015: A&A Biotechnology, AB ANALITICA, Abbott Molecular, Abcam, AccuGenomics, AdvanDx, Affymetrix, Agendia, Agilent, Alere (ClonDiag), Ameripath, Amoy Diagnostics, Amplisens, APB, Applied BioCode, Applied BioSystems (ABI), Arcxis Biotechnologies, Argene Inc (Biomerieux), Arrayit, Asuragen, Atlas Genetics, AutoGenomics, Axygen Products, Bayer, BD, Beckman Coulter, Biocartis, Biocept, Biodynamics, Biodyne, BioGenex, Biognost, BioHelix, Bioline, BioMerieux, Biometra, Bioneer, Bio-Rad, Bruker, Cancer Genetics, Caris Life Sciences, Cell Biolabs, Cell Signaling Technology, Cell-Marque, Cepheid, Clarient, Conda, Cooperative Diagnostics, Cytocell, Dako (Agilent), DDL, DermTech, ELITech Molecular, Empire Genomics, Enzo Life Sciences, Epigenomics, Eppendorf, Eurofins, Euroimmun, Experteem, Falcon Genomics, Fast track Diagnostics, Fermantas, Fluidigm, Focus Diagnostics, Foundation Medicine, GE Healthcare, Geneworks, GenMark Diagnostics, Genomica, Gen-Probe (Hologic), Gold Standard Diagnostics, Hain Life Science, Hemogenomics, Hologic, Hylabs, Idaho Technology, IDEXX, IDT, IDVET, Illumina, INBIO HIGHWAY, INEP, In-House Developed, Integrated Biotherapeutics, Interpath, Invitrogen (Life Technologies), Ipsogen (Qiagen), Kreatech Diagnostics, Lectinity, Leica, Life Technologies, Longgene, Luminex, Macherey-Nagel, MDxHealth, Merck, Meridian Bioscience, Metabion, Millipore, Mobio, MolecularMD, MP-Biomedicals, MRC-Holland, MWG Biotech, Myriad Genetics, Nanosphere, Nanostring, NeoGenomics, New England Biolabs, Novartis Diagnostics, Optigene, Orion Genomics, Other, OvaGene Oncology, Oxoid, Pacific Bioscience, Palex, Pathology, Peqlab, Primer Design, PrimeraDx, Promega, Qiagen, Quidel, R-Biopharm Inc, Roche Diagnostics, Sacace Biotechnologies, Santacruz, Seegene, SensiGen, Serosep Ltd., Shimadzu, Siemens, Sigma-aldrich, SinaGen, Solis Biodyne, Stratagene, Synbiotics, Sysmex, Takara, Thermo Fisher, TiBMolBiol, TwistDx, Ventana (Roche), Vircell, Virion, Vivantis, VWR, Zymo Research and Other.

Study1 2014: Abbott Molecular, AccuGenomics, AdnaGen, Affymetrix, Agendia, Amoy Diagnostics, Arcxis Biotechnologies, Arrayit, Asuragen, Autogenomics, Bayer, BD, Beckman Coulter, Biocartis, Biocept, BioGenex, BioHelix, bioMerieux, bioTheranostics (AviaraDx), Cancer Genetics, Inc, Cepheid, Chronix Biomedical, Cooperative Diagnostics, Cytocell, Da An Gene, Dako (Agilent), DermTech, Epigenomics, Gen-Probe, Hologic, Illumina, Invitrogen, Ipsogen (Qiagen), Kreatech Diagnostics, Luminex, MDxHealth, MolecularMD, Myriad Genetics, NeoGenomics, Novartis Diagnostics, Orion Genomics, Ortho-Clinical Diagnostics, OvaGene Oncology, PrimeraDx, Qiagen, Ribomed, Roche, SensiGen, Siemens, Sysmex, Thermo Fisher Scientific, Ventana (Roche) and any other organisations. 

8. CTC Markers: The markers participants work with in their current methods to enrich, isolate or identify CTC populations and, based on recent trends or developments in their work, the markers they anticipate using to enrich, isolate or identify CTC populations in three years from now.   The markers considered were were:

Study Dec 2015: ABC proteins, ABCG2, ABCG5, AKT, ALDH1, ALK, Androgen Receptor (AR), Bap1, Bcl-2, CCR6, CCR7, CCR9, CD127, CD133, CD133+ CXCR+-, CD146, CD166, CD176, CD26, CD38, CD44, CD44+CD24-, CD44v6, CD45- (Negative Select), CD63, CD90, Clusterin, c-Myc, CXCR4, cytochem – nuclei and nucleoli, Cytokeratins, cytomorphology, E-Cadherin, EGFR, EpCAM+, ER+, ERG, Fibronectin, Gama Catenin, Gamma-H2AX, HEA, HER2, HLA, ICAM-1, IGF-1R, M30, Muc1, Nanog, N-cadherin, Nestin, O-cadherin, Oestrogen- Progesterone- HER2-, PSA, PSMA, PSP94, PTEN, ROS1, Size, Snail1, Snail2, Tissue factor, TWIST1, Tyrosinase, UBB, VCAM-1, Vimentin and any others.

Study1 2014: EpCAM+, CD45- (negative select), Cytokeratins, ALDH1, CCR6, CCR7, CCR9, CD133, CD133+ CXCR+-, CD146, CD176, CD26, CD44, CD44+CD24-, CXCR4, EGFR, Fibronectin, HER2, ICAM-1, Muc1, N-cadherin, Nestin, O-cadherin, Oestrogen- Progesterone- HER2-, TWIST1, VCAM-1, Vimentin or any others.

9. CTC Subpopulations: Investigating whether participants work with more than one subpopulation of CTCs and, based on current trends or developments in their activities, whether they anticipate working with more than one subpopulation of CTCs in three year from now.    

Study Dec 2015: Apoptotic CTCs, Circulating endothelial cells, Circulating melanoma cells, Circulating tumour stem cells (CTSCs), CTC Clusters, CTC-macrophase hybrid cancer cells, Cytokeratin negative (CK-)  (CSCs), Epithelial tumour cells, Epithelial-to-mesenchymal transition (EMT) cells, Hybrid (epithelial/EMT+) tumour cells, Irreversible EMT+ tumour cells, Leukemic and lymphoma cells, Size-based separated cancer cells, Small CTCs (CK+/CD45-) and any others.

Study1 2014: Epithelial tumour cells, epithelial-to-mesenchymal transition (EMT) cells, hybrid (epithelial/EMT+) tumour cells, irreversible EMT+ tumour cells, circulating tumour stem cells (CTSCs) and any other subpopulations.

10. CTC Parameters or Measurements: The CTC measurements made by end-users in their CTC studies, both now and anticipated in three years. Here, the paramaters or measuremnts considered were:

Study Dec 2015: CTC levels (count), Differentiating CTC subtypes, CTC size or morphology, Time-dependent changes and any others.

11. Molecular Forms: The main nucleic acid forms that participants currently investigate or test for, in their CTC studies and, based on recent trends or developments in their work, the main nucleic acid forms they anticipate investigating or testing in their CTC activities in three years from now. The molecular forms considered were:

Study Dec 2015: Genomic DNA, Long non-coding RNAs (lncRNA), MicroRNA, Messenger RNA (mRNA), Necrotic ds DNA, Ribosomal DNA (rRNA), Small Interfering RNA (siRNA), Small Nuclear RNA (snRNA), Transfer RNA (tRNA) and any others.

Study1 2014: Genomic DNA, MicroRNA, Messenger RNA (mRNA), Ribosomal DNA (rRNA), Small Interfering RNA (siRNA), Small Nuclear RNA (snRNA), Transfer RNA (tRNA) or any other.

12. Molecular Biomarkers: The main CTC molecular biomarker types that participants identify or test for in their  current CTC activities and, based on recent trends or developments in their work, the main CTC molecular biomarker types that they anticipate identifying or testing in their CTC studies in three years from now. Here the markers considered included:

Study Dec 2015: Blood absolute DNA levels, Circulating DNA, DNA mismatch-repair genes (e.g. MLH1), Gene copy number, Gene expression (mRNA), Loss of heterozygosity (LOH), Methylation Events, MicroRNA, Microsatellite instability, Mitochondrial RNA (MtRNA), Mutation in tumour promoters (e.g. Ras)., Mutation of cell cycle genes (e.g. cyclins), Mutations in DNA repair proteins (e.g. XRCC1), Mutations in tumour suppressors (e.g. p53), Repetitive DNA sequences, Ribosomal RNA (rRNA), Small Interfering RNA (siRNA), Small Nuclear RNA (snRNA) Studies, SNPs, Transfer RNA, Translocation / fusion of genes and any others.

Study 1 2014: Blood absolute DNA levels, Circulating DNA, DNA mismatch-repair genes (e.g. MLH1), Epigenetic modifications (e.g. promoter methylation), Gene expression (mRNA), Loss of heterozygosity (LOH), MicroRNA, Microsatellite instability, Mitochondrial RNA (MtRNA), Mutation of cell cycle genes (e.g. cyclins), Mutation in tumour promoters (e.g. Ras)., Mutations in DNA repair proteins (e.g. XRCC1), Mutations in tumour suppressors (e.g. p53), Repetitive DNA sequences, Ribosomal RNA (rRNA), Small Interfering RNA (siRNA), Small Nuclear RNA (snRNA) Studies, Transfer RNA, Translocation / fusion of genes, Gene copy number and others.

13. Samples: The main sample types tested relating to participant's CTC activities, where the study samples considered were:

Study Dec 2015: Ascites, Biopsies, Blood (Whole/Peripheral), Bone marrow, Bronchial aspirate, Cell cultures, Cell Lines, Cerebrospinal Fluid (CSF), Formalin fixed/Paraffin embedded tissues, Nipple aspirate, Peritoneal washings, Plasma, Pleural effusion, Saliva, Serum, Sputum, Tissue (tumour), Urine and any others.

Study1 2014: Bronchial aspirate, CSF, nipple aspirate, plasma, saliva, serum, sputum, urine, whole blood or other samples.

14. Clinical Utilities
: The main clinical utilities of CTCs in participant's current cancer diagnostic or treatment-related activities and, based on recent trends or developments in their work, what they anticipate will be the main clinical utilities of CTCs in their cancer diagnostic or treatment-related activities, in three years from now. Here the clinical utilities considered were:

Study Dec 2015: CTC-specific therapeutic immunity, Disease susceptibility or risk, Early detection of disease, Identification of primary disease, Disease stage or severity, Tumour burden, Metastatic disease, Guiding treatment, Response to therapy, Following course of disease, Residual disease, Disease prognosis, Safety or toxicity factors, Drug discovery, Clinical trial subject inclusion/exclusion, Clinical trial endpoint, Other, Not Applicable and any others.

Study 1 2014: Disease susceptibility or risk, Early detection of disease, Identification of primary disease, Disease stage or severity, Tumour burden, Metastatic disease, Guiding treatment, Response to therapy, Following course of disease, Residual disease, Disease prognosis, Safety or toxicity factors, Drug discovery, Clinical trial subject inclusion/exclusion, Clinical trial endpoint or others.

15. Cancers: The main cancer types with which participants currently work, relating to their CTC activities. Here, the cancers considered were:  

Study Dec 2015: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), AIDS-Related, Bladder, Bone, Brain & Spinal Cord, Breast, Cervical, Childhood, Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML), Colorectal, Esophageal, Eye, Head and Neck, Hodgkin Lymphoma, Kidney, Liver, Lung, Melanoma, Mesothelioma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma, Oesophageal, Oral squamous cell carcinoma, Ovarian, Pancreatic, Prostate, Retinoblastoma, Skin, Stomach, Testicular, Thyroid, Uterine and any others.

Study1 2014: Acute Lymphoblastic Leukaemia (ALL), Acute Myeloid Leukaemia (AML), AIDS-Related, Bladder, Bone, Brain & Spinal Cord, Breast, Cervical, Childhood, Chronic Lymphocytic Leukaemia (CLL), Chronic Myelogenous Leukaemia (CML), Colorectal, Head and Neck, Hodgkin Lymphoma, Kidney, Liver, Lung, Non-Hodgkin Lymphoma, Oesophageal, Ovarian, Pancreatic, Prostate, Skin, Stomach, Testicular, Thyroid, Uterine and any others.

16. Purpose: The propose of participants work relating to CTCs in clinical, laboratory research or drug R&D.

Study Dec 2015: CLINICAL: Clinical research or disease research, CLINICAL: Patient screening or diagnostics, CLINICAL: Patient treatment, CLINICAL: Other, DIAGNOSTICS: In-vitro cultures, DIAGNOSTICS: Patient testing, DIAGNOSTICS: Research, DIAGNOSTICS: New test development, DIAGNOSTICS: Other, DRUG R&D: Biomarker research, DRUG R&D: Clinical studies, DRUG R&D: Diagnostics research, DRUG R&D: Disease research, DRUG R&D: Drug targets, DRUG R&D: Other, DRUG R&D: Preclinical studies, LABORATORY RESEARCH: Biomarker research, LABORATORY RESEARCH: Clinical studies, LABORATORY RESEARCH: Diagnostics research, LABORATORY RESEARCH: Disease research, LABORATORY RESEARCH: Drug targets, LABORATORY RESEARCH: Preclinical studies, LABORATORY RESEARCH and any others.

Study1 2014: Clinical areas included  clinical research or disease research, patient screening or diagnostics, patient treatment or other areas; Laboratory research areas included disease research, drug targets, preclinical studies, clinical studies, biomarker research, diagnostics research or other areas and drug R&D covered disease research, drug targets, preclinical studies, clinical studies, biomarker research, diagnostics research or other areas.

17. Limitations: Based on the current status or CTC testing, what participants believe are the greatest limitations in your own work on CTCs.

Study Dec 2015: Amplification of low-expression biomarkers, Antibodies nonspecificity, Assay accuracy, Assay sensitivity, Assay time requirements, Assay validation, Automation, Clinical usefulness, Clinician cooperation, Cloning limitations, Collaboration opportunities, Consistent molecular analysis, Corroboration of CTC evidence, Costs, CTC contamination with white cells, CTC culturing, CTC isolation, CTC purity, CTC Stability, CTC sub-population identification, Detectable markers, Enrichment methods, Expertise availability, FDA approval, Funding, Instrument limitations, Knowledge limits, Labour intensiveness, Mainstream acceptance, Manpower availability, Patient sample quality, Reimbursement issues, Training requirements, Whole blood isolation and any others.

18. Role: Participants role in the cancer field (Physician or Clinician, Laboratory Scientist (Clinical or Other), Laboratory or Clinical Manager, Veterinarian and Other.

19. Participants: Participants provided background information on themselves and their activities including professional positions, activities, email address of the organisation (company, university etc.) to which their cancer activities relate; region (Europe, Asia, North America, South America, Africa (Sub-Saharan), Central America / Caribbean, Australia, New Zealand and Oceania and Middle East / North Africa / and Greater Arabia); countries; professional title; years of experience in cancer the cancer field; organisation type (Clinic, Government Organisation, Hospital, Large International Company, Medium Sized Company, Research Institute, Small Company, Teaching Hospital, University, Veterinary Organisation, Other and If other, please indicate); role; Physician or Clinician, Laboratory Scientist (Clinical or Other), Laboratory or Clinical Manager, Veterinarian or any other and purpose of work relating to CTCs; CLINICAL: Clinical research or disease research, CLINICAL: Patient screening or diagnostics, CLINICAL: Patient treatment, CLINICAL: other, LABORATORY RESEARCH: Disease research, LABORATORY RESEARCH: Drug targets, LABORATORY RESEARCH: Preclinical studies, LABORATORY RESEARCH: Clinical studies, LABORATORY RESEARCH: Biomarker research, LABORATORY RESEARCH: Diagnostics research, LABORATORY RESEARCH: other, DRUG R&D: Disease research, DRUG R&D: Drug targets, DRUG R&D: Preclinical studies, DRUG R&D: Clinical studies, DRUG R&D: Biomarker research, DRUG R&D: Diagnostics research or DRUG R&D: other.

20. Drug R&D

Study Dec 2015: Participants use of CTCs for the purpose of drug R&D now and anticipated in three years and the stages of drug r&d that your work on CTCs relate, namely Early research, Preclinical studies, Phase 1, Phase 2, Phase 3 and Phase 4 post market.

Study1 2014: Early-Stage Drug Research: The use of CTCs in early-stage drug research and, based on current trends or developments in their work, their anticipation of using CTCs in early-stage drug research in three years from now. Preclinical Drug R&D: The use of CTCs in preclinical drug research and, based on current trends or developments in their work, their anticipation of using CTCs in preclinical drug research in three years from now. Clinical Drug R&D: The use of CTCs in clinical drug research and, based on current trends or developments in their work, their anticipation of using CTCs in clinical drug research in three years from now. Clinical Trial End-Points: The use of CTC measurements or parameters as clinical trial end-points and, based on current trends or developments, their anticipation of using CTC measurements or parameters as clinical trial end-points in their clinical studies in three years from now.

21. Companion Diagnostics

Study Dec 2015: The use of CTCs in the development or use of companion diagnostics, now and anticipated in three years.

Study1 2014: the use of CTCs as part of companion diagnostics in their current activities and, based on current trends or developments in their work, their anticipation of using CTCs as part of companion diagnostic developments in three years from now.

Circulating Nucleic Acids

1. Growth

Study Dec 2015: Participants estimates of by how much (% increase or % decrease) their  laboratory's work with cfDNA and cfRNA has changed (or not) over the last three years. Also, based on current trends in the number of cfDNA and cfRNA tests (i.e. number of assays) carried out in your laboratory, participants estimates by how much (% increase or % decrease) they anticipate their cfDNA and cfRNA activities will change (or not) over the next three years.

Study1 2014: Participants estimates of by how much (% increase or % decrease) their  laboratory's work with circulating nucleic acids has changed (or not) over the last three years. Also, based on current trends in the number of circulating nucleic acids tests (i.e. number of assays) carried out in your laboratory, participants estimates by how much (% increase or % decrease) they anticipate their circulating nucleic acids activities will change (or not) over the next three years.

2. CTC Test Costs Participants estimates of the current per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for CNA.

Study Dec 2015: End-users' estimates of current per-patient test costs for CTCs.

Study1 2014: End-users' estimates of current per-patient test costs for CTCs.

3. Molecular Techniques: The main molecular characterisation techniques that participants currently use, in your circulating nucleic acid (CNA) studies and, based on current trends and developments in their work, the main molecular characterisation techniques that they anticipate using in their CNA studies in three year from now. The techniques considered were

Study Dec 2015: Allele-specific PCR, Arbitrarily Primed PCR (AP-PCR), Assembly PCR (Polymerase Cycling Assembly, PCA), Asymmetric PCR (A PCR), bDNA assays, Bead-Emulsion Amplification PCR (BEA), Cancer BioChip System, Classical qualitative PCR, Colony PCR, Comet assay, Conventional qualitative PCR, Cycling Probe Technology, Cytogenetic banding, Degenerate Oligonucleotide PCR (DOP-PCR), Denaturing Gradient Gel Electrophoresis (DGGE), Digital PCR (dPCR), DNA biosensors, DNA cloning, General Hybridization, General Primers PCR, Genome Expression Profiling System (GeXP), Helicase-Dependent Amplification, High resolution melting (HRM), Hot start PCR, Hybrid Capture Assay, Hyper-PCR, Immunocapture PCR, In Situ Hybridization (e.g. FISH), In-Silico PCR, Intersequence-specific PCR (ISSR), Inverse PCR, Isothermal PCR, Karyotyping (chromosomes), Ligase Chain Reaction, Ligation-Mediated PCR, Liquid Hybridization, LNA PCR, Long PCR, Loop-mediated isothermal amplification (LAMP), Methylation-Specific PCR (MSP), Microarrays, Microsphere-Based Array, Miniprimer PCR, Multilocus Sequence Typing (MLST), Multiple Loci VNTR Analysis (MLVA), Multiplex Ligation-Dependent Probe Amplification (MLPA), Multiplex PCR, Multiplex Real-Time PCR, Multiplex Taqman, Multiplexed Microsphere-Based Array, Nested PCR, Next-Generation Sequencing (NGS), Northern Blot, Nucleic Acid Sequence-Based Amplification (NASBA), Other, Overlap-Extension PCR ( Splicing by overlap extension, SOE), PAN-AC (Single Reaction Real Time PCR), Panbacterial PCR, PCR array, PCR Denaturing Gradient Gel Electrophoresis (PCR DGGE), PCR Restriction Fragment Length Polymorphism (PCR-RFLP), Phylogenetic Community Analysis, Pulsed Field Gel Glectrophoresis (PFGE), Random Amplified Polymorphic DNA (RAPD), Rapid Amplification of cDNA ENDS PCR (RACE PCR), Rapid test, Real Time/Quantitative PCR (qPCR), Restriction Fragment Length Polymorphism (RFLP), Reverse Transcription PCR (RT-PCR), RNA-seq (Whole Transcriptome), Sanger sequencing, Single molecule PCR, Single nucleotide repeat (SNR), Single Specific Primer-Polymerase Chain Reaction (SSP-PCR), Single tube Nested-PCR, Solid Phase PCR, Southern Blot, Stem loop RT PCR, Stepdown PCR, Strand Displacement Amplification, TaqMan Real Time PCR, Techniques not requiring amplification, Temporal Temperature Gradient Gel Electrophoresis (PCR-TTGE), Thermal Asymmetric Interlaced PCR (TAIL-PCR), Touchdown PCR, Transcription-Mediated Amplification (TMA), Type-Specific PCR, Universal Fast Walking, Whole genome amplification, Other and Other (please specify).

Study1 2014: Allele-specific PCR, Arbitrarily Primed PCR (AP-PCR), Assembly PCR (Polymerase Cycling Assembly, PCA), Asymmetric PCR (A PCR), Bead-Emulsion Amplification PCR (BEA), Classical qualitative PCR, Colony PCR, Degenerate Oligonucleotide PCR (DOP-PCR), Digital PCR (dPCR), DNA cloning, Hot start PCR, Immunocapture PCR, In Situ Hybridization (e.g. FISH), In-Silico PCR, Inverse PCR, Isothermal PCR, Ligation-Mediated PCR, Long PCR, Methylation-Specific PCR (MSP), Microarrays, Miniprimer PCR, Multiplex Ligation-Dependent Probe Amplification (MLPA), Multiplex PCR, Multiplex Real-Time PCR, Multiplex Taqman, Nested PCR, Next-Generation Sequencing, Northern Blot, PAN-AC (Single Reaction Real Time PCR), PCR array, PCR Denaturing Gradient Gel Electrophoresis (PCR DGGE), PCR Restriction Fragment Length Polymorphism (PCR-RFLP), Real time PCR (qPCR), Random Amplified Polymorphic DNA (RAPD), Rapid Amplification of cDNA ENDS PCR (RACE PCR), Reverse Transcription PCR (RT-PCR), Sequencing (Sanger), Single molecule PCR, Single Specific Primer-Polymerase Chain Reaction (SSP-PCR), Solid Phase PCR, Southern Blot, Stem loop RT PCR, Taqman, Temporal Temperature Gradient Gel Electrophoresis (PCR-TTGE), Touchdown PCR, Transcription-Mediated Amplification (TMA) and other techniques.

4. Molecular Suppliers:  The main current suppliers (molecular systems, kits, reagents of molecular methods (e.g. Systems, kits, reagents), relating to participant's circulating nucleic acid (CNA) investigations and, based on current trends or developments in their work, the main suppliers of molecular methods (e.g. Systems, kits, reagents) that participants anticipate purchasing from in three years from now. The organisations considered were:

Study Dec 2015: A&A Biotechnology, AB ANALITICA, Abbott Molecular, Abcam, AccuGenomics, AdvanDx, Affymetrix, Agendia, Agilent, Alere (ClonDiag), Ameripath, Amoy Diagnostics, Amplisens, APB, Applied BioCode, Applied BioSystems (ABI), Arcxis Biotechnologies, Argene Inc (Biomerieux), Arrayit, Asuragen, Atlas Genetics, AutoGenomics, Axygen Products, Bayer, BD, Beckman Coulter, Biocartis, Biocept, Biodynamics, Biodyne, BioGenex, Biognost, BioHelix, Bioline, BioMerieux, Biometra, Bioneer, Bio-Rad, Bruker, Cancer Genetics, Caris Life Sciences, Cell Biolabs, Cell Signaling Technology, Cell-Marque, Cepheid, Clarient, Conda, Cooperative Diagnostics, Cytocell, Dako (Agilent), DDL, DermTech, ELITech Molecular, Empire Genomics, Enzo Life Sciences, Epigenomics, Eppendorf, Eurofins, Euroimmun, Experteem, Falcon Genomics, Fast track Diagnostics, Fermantas, Fluidigm, Focus Diagnostics, Foundation Medicine, GE Healthcare, Geneworks, GenMark Diagnostics, Genomica, Gen-Probe (Hologic), Gold Standard Diagnostics, Hain Life Science, Hemogenomics, Hologic, Hylabs, Idaho Technology, IDEXX, IDT, IDVET, Illumina, INBIO HIGHWAY, INEP, In-House Developed, Integrated Biotherapeutics, Interpath, Invitrogen (Life Technologies), Ipsogen (Qiagen), Kreatech Diagnostics, Lectinity, Leica, Life Technologies, Longgene, Luminex, Macherey-Nagel, MDxHealth, Merck, Meridian Bioscience, Metabion, Millipore, Mobio, MolecularMD, MP-Biomedicals, MRC-Holland, MWG Biotech, Myriad Genetics, Nanosphere, Nanostring, NeoGenomics, New England Biolabs, Novartis Diagnostics, Optigene, Orion Genomics, Other, OvaGene Oncology, Oxoid, Pacific Bioscience, Palex, Pathology, Peqlab, Primer Design, PrimeraDx, Promega, Qiagen, Quidel, R-Biopharm Inc, Roche Diagnostics, Sacace Biotechnologies, Santacruz, Seegene, SensiGen, Serosep Ltd., Shimadzu, Siemens, Sigma-aldrich, SinaGen, Solis Biodyne, Stratagene, Synbiotics, Sysmex, Takara, Thermo Fisher, TiBMolBiol, TwistDx, Ventana (Roche), Vircell, Virion, Vivantis, VWR, Zymo Research and Other.

Study1 2014: Abbott Molecular, AccuGenomics, AdnaGen, Affymetrix, Agendia, Amoy Diagnostics, Arcxis Biotechnologies, Arrayit, Asuragen, Autogenomics, Bayer, BD, Beckman Coulter, Biocartis, Biocept, BioGenex, BioHelix, bioMerieux, bioTheranostics (AviaraDx), Cancer Genetics, Inc, Cepheid, Chronix Biomedical, Cooperative Diagnostics, Cytocell, Da An Gene, Dako (Agilent), DermTech, Epigenomics, Gen-Probe, Hologic, Illumina, Invitrogen, Ipsogen (Qiagen), Kreatech Diagnostics, Luminex, MDxHealth, MolecularMD, Myriad Genetics, NeoGenomics, Novartis Diagnostics, Orion Genomics, Ortho-Clinical Diagnostics, OvaGene Oncology, PrimeraDx, Qiagen, Ribomed, Roche, SensiGen, Siemens, Sysmex, Thermo Fisher Scientific, Ventana (Roche) and any other organisations. 

5. Kits and Suppliers:Participants' preferred kit and supplier for their work on the enrichment/isolation of circulating cell-free dna/rna (cfDNA/cfRNA)

6. Molecular Forms: The main nucleic acid forms that participants currently investigate or test for, in their CNA studies and, based on recent trends or developments in their work, the main nucleic acid forms they anticipate investigating or testing in their CNA activities in three years from now. The molecular forms considered were:

Study Dec 2015: Genomic DNA, Long non-coding RNAs (lncRNA), MicroRNA, Messenger RNA (mRNA), Necrotic ds DNA, Ribosomal DNA (rRNA), Small Interfering RNA (siRNA), Small Nuclear RNA (snRNA), Transfer RNA (tRNA) and any others.

Study1 2014: Genomic DNA, MicroRNA, Messenger RNA (mRNA), Ribosomal DNA (rRNA), Small Interfering RNA (siRNA), Small Nuclear RNA (snRNA), Transfer RNA (tRNA) or any other.

7. Molecular Biomarkers: The main CNA molecular biomarker types that participants identify or test for in their  current CNA activities and, based on recent trends or developments in their work, the main CNA molecular biomarker types that they anticipate identifying or testing in their CNA studies in three years from now. Here the markers considered included:

Study Dec 2015: Blood absolute DNA levels, Circulating DNA, DNA mismatch-repair genes (e.g. MLH1), Gene copy number, Gene expression (mRNA), Loss of heterozygosity (LOH), Methylation Events, MicroRNA, Microsatellite instability, Mitochondrial RNA (MtRNA), Mutation in tumour promoters (e.g. Ras)., Mutation of cell cycle genes (e.g. cyclins), Mutations in DNA repair proteins (e.g. XRCC1), Mutations in tumour suppressors (e.g. p53), Repetitive DNA sequences, Ribosomal RNA (rRNA), Small Interfering RNA (siRNA), Small Nuclear RNA (snRNA) Studies, SNPs, Transfer RNA, Translocation / fusion of genes, Other and any others.

Study1 2014: Blood absolute DNA levels, Circulating DNA, DNA mismatch-repair genes (e.g. MLH1), Epigenetic modifications (e.g. promoter methylation), Gene expression (mRNA), Loss of heterozygosity (LOH), MicroRNA, Microsatellite instability, Mitochondrial RNA (MtRNA), Mutation of cell cycle genes (e.g. cyclins), Mutation in tumour promoters (e.g. Ras)., Mutations in DNA repair proteins (e.g. XRCC1), Mutations in tumour suppressors (e.g. p53), Repetitive DNA sequences, Ribosomal RNA (rRNA), Small Interfering RNA (siRNA), Small Nuclear RNA (snRNA) Studies, Transfer RNA, Translocation / fusion of genes, Gene copy number and others.

8. Samples: The main sample types tested relating to participant's circulating nucleic acid (CNA) activities, including

Study Dec 2015: Ascites, Biopsies, Blood (Whole/Peripheral), Bone marrow, Bronchial aspirate, Cell cultures, Cell Lines, Cerebrospinal Fluid (CSF), Formalin fixed/Paraffin embedded tissues, Nipple aspirate, Peritoneal washings, Plasma, Pleural effusion, Saliva, Serum, Sputum, Tissue (tumour), Urine and any others.

Study1 2014: Bronchial aspirate, CSF, nipple aspirate, plasma, saliva, serum, sputum, urine, whole blood or other samples.

9. Clinical Utilities: The main clinical utilities of CNAs in participant's current cancer diagnostic or treatment-related activities and, based on recent trends or developments in their work, what they anticipate will be the main clinical utilities of CNAs in their cancer diagnostic or treatment-related activities, in three years from now. Here the clinical utilities considered were:

Study Dec 2015: CTC-specific therapeutic immunity, Disease susceptibility or risk, Early detection of disease, Identification of primary disease, Disease stage or severity, Tumour burden, Metastatic disease, Guiding treatment, Response to therapy, Following course of disease, Residual disease, Disease prognosis, Safety or toxicity factors, Drug discovery, Clinical trial subject inclusion/exclusion, Clinical trial endpoint, Other, Not Applicable and any others.

Study1 2014: Disease susceptibility or risk, Early detection of disease, Identification of primary disease, Disease stage or severity, Tumour burden, Metastatic disease, Guiding treatment, Response to therapy, Following course of disease, Residual disease, Disease prognosis, Safety or toxicity factors, Drug discovery, Clinical trial subject inclusion/exclusion, Clinical trial endpoint or others.

10. Diseases: The main disease areas that you anticipate working with in your circulating cell-free DNA and RNA relate (cfDNA and cfRNA) now and in three years, where the diseases considered were:

Study Dec 2015: Ageing, Allergy, Arthritis, Asthma, Autoimmune, Bacterial infections, Blood diseases, Bone, Bone metabolism, Brain damage, Cancer, Cardiac, Cardiometabolic, Cardiovascular, Cartilage, Celiac Disease, Central nervous system, Coagulation, Connective Tissue, Dermatology, Diabetes, Endocrinology, Epidemiology, Fertility, Food Intolerance, Fungal infections, Gastrointestinal, Genetic diseases, Genito-urinary system, Haematology, Hepatitis, Hypertension, Immune system, Inflammation, Liver Disease, Metabolic disorders, Musculoskeletal disorders, Neurodegenerative diseases, Neuromuscular, Newborn screening, Nutrition, Obesity, Obstetrics and Gynaecology, Ophthalmology, Pain, Parasitology, Plant Health, Pregnancy, Reproduction, Respiratory, Sexually Transmitted, Skin, Smoking, Thrombosis/Coagulation, Thyroid Diseases, Toxicology, Tropic al Diseases, Vascular disease, Vasculitis, Veterinary, Viral infections, Vitamin deficiencies, Women's Health, and any others.

11. Cancers: The main cancer types with which participants currently work, relating to their CNA activities. Here, the cancers considered were:

Study Dec 2015: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), AIDS-Related, Bladder, Bone, Brain & Spinal Cord, Breast, Cervical, Childhood, Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML), Colorectal, Esophageal, Eye, Head and Neck, Hodgkin Lymphoma, Kidney, Liver, Lung, Melanoma, Mesothelioma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma, Oesophageal, Oral squamous cell carcinoma, Ovarian, Pancreatic, Prostate, Retinoblastoma, Skin, Stomach, Testicular, Thyroid, Uterine, Other, Not Applicable and any others.

Study1 2014: Acute Lymphoblastic Leukaemia (ALL), Acute Myeloid Leukaemia (AML), AIDS-Related, Bladder, Bone, Brain & Spinal Cord, Breast, Cervical, Childhood, Chronic Lymphocytic Leukaemia (CLL), Chronic Myelogenous Leukaemia (CML), Colorectal, Head and Neck, Hodgkin Lymphoma, Kidney, Liver, Lung, Non-Hodgkin Lymphoma, Oesophageal, Ovarian, Pancreatic, Prostate, Skin, Stomach, Testicular, Thyroid, Uterine and any others.

12. Purpose: The propose of participants work relating to CNAs in clinical, laboratory research or drug R&D. Clinical areas included 

Study Dec 2015: CLINICAL: Clinical research or disease research, CLINICAL: Patient screening or diagnostics, CLINICAL: Patient treatment, CLINICAL: Other, DIAGNOSTICS: In-vitro cultures, DIAGNOSTICS: Patient testing, DIAGNOSTICS: Research, DIAGNOSTICS: New test development, DIAGNOSTICS: Other, DRUG R&D: Biomarker research, DRUG R&D: Clinical studies, DRUG R&D: Diagnostics research, DRUG R&D: Disease research, DRUG R&D: Drug targets, DRUG R&D: Other, DRUG R&D: Preclinical studies, LABORATORY RESEARCH: Biomarker research, LABORATORY RESEARCH: Clinical studies, LABORATORY RESEARCH: Diagnostics research, LABORATORY RESEARCH: Disease research, LABORATORY RESEARCH: Drug targets, LABORATORY RESEARCH: Preclinical studies, LABORATORY RESEARCH: Other.

Study1 2014: clinical research or disease research, patient screening or diagnostics, patient treatment or other areas; Laboratory research areas included disease research, drug targets, preclinical studies, clinical studies, biomarker research, diagnostics research or other areas and drug R&D covered disease research, drug targets, preclinical studies, clinical studies, biomarker research, diagnostics research or other areas.

13. Limitations of Circulating Nucleic Acid (CNA) Studies : Based on the current status or CNA testing, what participants believe are the greatest limitations in your own work on CNAs.

Study Dec 2015: Access to retrospective samples, Accuracy, Assay robustness, Assay sensitivity, Automation, Clinical sample quality, Clinical usefulness, Clinician cooperation, Costs, Database availability, Determining cellular origins, DNA contamination, DNA extraction, DNA stability, Epigenetic modification assays, Expertise availability, Extraction kit availability, False positives, FDA approval, Fragmentation of DNA, Funding, Instrument limitations, Knowledge limits, Lack of evidence of clinical value, Lack of novel biomarkers, Limited amount of material, low amount of sample, Mainstream acceptance, Manpower availability, Need for reference groups, Quantifying amount of ctDNA in early stages, Reimbursement issues, Reproducibility, RNA extraction, Sample collection methods, Sample stability, Sample storage, Selection of microRNA for testing, Time requirements, Training requirements, Transport and stabilisation, Validated procedures, Variability in DNA levels, Whole blood isolation, Other and Other (please specify).

14. Role: Participants role in the cancer field (Physician or Clinician, Laboratory Scientist (Clinical or Other), Laboratory or Clinical Manager, Veterinarian and Other.

15. Drug R&D

Study1 2014: Early-Stage Drug Research: The use of CNAs in early-stage drug research and, based on current trends or developments in their work, their anticipation of using CNAs in early-stage drug research in three years from now. Preclinical Drug R&D: The use of CTCs in preclinical drug research and, based on current trends or developments in their work, their anticipation of using CTCs in preclinical drug research in three years from now. Clinical Drug R&D: The use of CTCs in clinical drug research and, based on current trends or developments in their work, their anticipation of using CTCs in clinical drug research in three years from now. Clinical Trial End-Points: The use of CTC measurements or parameters as clinical trial end-points and, based on current trends or developments, their anticipation of using CTC measurements or parameters as clinical trial end-points in their clinical studies in three years from now.

Study Dec 2015: Participants use of CTCs for the purpose of drug R&D now and anticipated in three years and the stages of drug r&d that your work on CTCs relate, namely Early research, Preclinical studies, Phase 1, Phase 2, Phase 3 and Phase 4 post market.

16. Companion Diagnostics

Study Dec 2015: The use of CNAs in the development or use of companion diagnostics now and in three years

Study1 2014: the use of CTCs as part of companion diagnostics in their current activities and, based on current trends or developments in their work, their anticipation of using CTCs as part of companion diagnostic developments in three years from now.

17. Participants: Participants provided background information on themselves and their activities including professional positions, activities, email address of the organisation (company, university etc.) to which their cancer activities relate; region (Europe, Asia, North America, South America, Africa (Sub-Saharan), Central America / Caribbean, Australia, New Zealand and Oceania and Middle East / North Africa / and Greater Arabia); countries; professional title; years of experience in cancer the cancer field; organisation type (Clinic, Government Organisation, Hospital, Large International Company, Medium Sized Company, Research Institute, Small Company, Teaching Hospital, University, Veterinary Organisation,

Exosomes

1. Working with Exosomes: The study or investigation of exosomes currently and anticipated in three years.

2. Disease Areas: The disease areas to which participants' exosome activities relate:

Study Dec 2015: Ageing, Allergy, Arthritis, Asthma, Autoimmune, Bacterial infections, Blood diseases, Bone, Bone metabolism, Brain damage, Cancer, Cardiac, Cardiometabolic, Cardiovascular, Cartilage, Celiac Disease, Central nervous system, Coagulation, Connective Tissue, Dermatology, Diabetes, Endocrinology, Epidemiology, Fertility, Food Intolerance, Fungal infections, Gastrointestinal, Genetic diseases, Genito-urinary system, Haematology, Hepatitis, Hypertension, Immune system, Inflammation, Liver Disease, Metabolic disorders, Musculoskeletal disorders, Neurodegenerative diseases, Neuromuscular, Newborn screening, Nutrition, Obesity, Obstetrics and Gynaecology, Ophthalmology, Pain, Parasitology, Plant Health, Pregnancy, Reproduction, Respiratory, Sexually Transmitted, Skin, Smoking, Thrombosis/Coagulation, Thyroid Diseases, Toxicology, Tropic al Diseases, Vascular disease, Vasculitis, Veterinary, Viral infections, Vitamin deficiencies, Women's Health, Other and Other (please specify).

3. Kits and Suppliers: Participants preferred kit and supplier for their work on the isolation of exosomes

 

 

 

  •